Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St headed for weekly gains as earnings season nears
- Oil falls as Trump comments on Iran talks ease supply fears
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $4.57 +0.88%
Revenue Growth %: +23.2%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
HOVR, VFS, PGR, More
Revenue Growth %: +23.2%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
HOVR, VFS, PGR, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of $0.00, $0.04 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $38.82 million versus the consensus estimate of $44.5 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- UBS Reiterates Buy Rating on Pepsico (PEP) on Q3 Beat
- UBS Reiterates Buy Rating on EMCOR Group (EME) Into Q3 Earnings
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
